Skip to main content

The AHRQ National Quality Measures Clearinghouse (NQMC, qualitymeasures.ahrq.gov) Web site will not be available after July 16, 2018 because federal funding
through AHRQ will no longer be available to support the NQMC as of that date. For additional information, read our full announcement.
  • Measure Summary
  • NQMC:010991
  • Dec 2016

Lung cancer: percentage of patients with clinical stage IB or higher, but no evidence of metastatic disease, who have had a mediastinal lymph node sampling procedure performed prior to the initiation of curative intent therapy.

American College of Chest Physicians (CHEST). Quality indicators for the evaluation of patients with lung cancer: quality indicator descriptions. Glenview (IL): American College of Chest Physicians (CHEST); 2016 Dec 1. 3 p.

This is the current release of the measure.

Primary Measure Domain

Clinical Quality Measures: Process

Secondary Measure Domain

Does not apply to this measure

Description

This measure is used to assess the percentage of patients with clinical stage IB or higher, but no evidence of metastatic disease, who have had a mediastinal lymph node sampling procedure performed prior to the initiation of curative intent therapy.

Rationale

Patients with clinical stage IB or higher have a clinically significant likelihood of having undetected mediastinal lymph node metastases. Treatment of regionally metastatic lung cancer is different than localized lung cancer. Treatment of regionally metastatic lung cancer is more successful if detected prior to the initiation of curative intent therapy.

Evidence for Rationale

American College of Chest Physicians (CHEST). Quality indicators for the evaluation of patients with lung cancer: quality indicator descriptions. Glenview (IL): American College of Chest Physicians (CHEST); 2016 Dec 1. 3 p.

Primary Health Components

Lung cancer; mediastinal lymph node sampling procedure; curative intent therapy

Denominator Description

All patients with clinical stage IB or higher, but no evidence of metastatic disease, who have had curative intent therapy

Numerator Description

Patients with clinical stage IB or higher, but no evidence of metastatic disease, who have had a mediastinal lymph node sampling procedure performed prior to the initiation of curative intent therapy

Type of Evidence Supporting the Criterion of Quality for the Measure

  • A clinical practice guideline or other peer-reviewed synthesis of the clinical research evidence
  • A formal consensus procedure, involving experts in relevant clinical, methodological, public health and organizational sciences

Additional Information Supporting Need for the Measure

Unspecified

Extent of Measure Testing

Unspecified

State of Use

Pilot testing

Current Use

Internal quality improvement

National Quality Strategy Aim

Better Care

National Quality Strategy Priority

Prevention and Treatment of Leading Causes of Mortality

IOM Care Need

Living with Illness

IOM Domain

Effectiveness

Case Finding Period

Unspecified

Denominator Sampling Frame

Patients associated with provider

Denominator (Index) Event or Characteristic

Clinical Condition

Therapeutic Intervention

Denominator Time Window

Does not apply to this measure

Denominator Inclusions/Exclusions

Inclusions
All patients with clinical stage IB or higher, but no evidence of metastatic disease, who have had curative intent therapy

Exclusions
Unspecified

Exclusions/Exceptions

Unspecified

Numerator Inclusions/Exclusions

Inclusions
Patients with clinical stage IB or higher, but no evidence of metastatic disease, who have had a mediastinal lymph node sampling procedure performed prior to the initiation of curative intent therapy

Exclusions
Unspecified

Numerator Search Strategy

Fixed time period or point in time

Data Source

Electronic health/medical record

Paper medical record

Type of Health State

Does not apply to this measure

Instruments Used and/or Associated with the Measure

Unspecified

Measure Specifies Disaggregation

Does not apply to this measure

Scoring

Rate/Proportion

Interpretation of Score

Desired value is a higher score

Allowance for Patient or Population Factors

Unspecified

Standard of Comparison

Internal time comparison

Original Title

Percentage of patients with clinical stage IB or higher, but no evidence of metastatic disease, who have had a mediastinal lymph node sampling procedure performed prior to the initiation of curative intent therapy.

Measure Collection Name

Quality Indicators for the Evaluation of Patients with Lung Cancer

Submitter

American College of Chest Physicians - Medical Specialty Society

Developer

American College of Chest Physicians - Medical Specialty Society

Funding Source(s)

The authors have reported to CHEST that no funding was received for this study.

Composition of the Group that Developed the Measure

A core group of specialists with an interest in the evaluation and staging of lung cancer was recruited from the Thoracic Oncology Network and Quality Improvement Committee of the American College of Chest Physicians (CHEST). The six members included three pulmonologists and three thoracic surgeons.

Authors: Peter J. Mazzone, MD, FCCP; Anil Vachani, MD, FCCP; Andrew Chang, MD, FCCP; Frank Detterbeck, MD, FCCP; David Cooke, MD, FCCP; John Howington, MD, FCCP; Amos Dodi, MD; Douglas Arenberg, MD, FCCP

Financial Disclosures/Other Potential Conflicts of Interest

The authors have reported to CHEST the following conflicts of interest:

  • Dr. Vachani has received research grants from Allegro Diagnostics Corp., Integrated Diagnostics, Inc., Genentech, and Transgenomic, Inc., and advisory board fees from Allegro Diagnostics Corp. and Genentech.
  • Drs. Mazzone, Chang, Detterbeck, Cooke, Howington, Dodi, and Arenberg have reported that no potential conflicts of interest exist with any companies/organizations whose products or services may be discussed in this article.

Adaptation

This measure was not adapted from another source.

Date of Most Current Version in NQMC

2016 Dec

Measure Maintenance

Unspecified

Date of Next Anticipated Revision

Unspecified

Measure Status

This is the current release of the measure.

Source(s)

American College of Chest Physicians (CHEST). Quality indicators for the evaluation of patients with lung cancer: quality indicator descriptions. Glenview (IL): American College of Chest Physicians (CHEST); 2016 Dec 1. 3 p.

Measure Availability

Source not available electronically.

For more information, contact the American College of Chest Physicians (CHEST) at 2595 Patriot Boulevard, Glenview, IL 60026; Phone: Phone: 224-521-9800; Fax: 224-521-9801; Web site: www.chestnet.org External Web Site Policy.

Companion Documents

The following is available:

  • Mazzone PJ, Vachani A, Chang A, Detterbeck F, Cooke D, Howington J, Dodi A, Arenberg D. Quality indicators for the evaluation of patients with lung cancer. Chest. 2014 Sep;146(3):659-69. This document is available for purchase from the CHEST Journal Web site External Web Site Policy.

NQMC Status

This NQMC summary was completed by ECRI Institute on January 23, 2017. The information was verified by the measure developer on March 2, 2017.

Copyright Statement

This NQMC summary is based on the original measure, which is subject to the measure developer's copyright restrictions.

For more information, contact the American College of Chest Physicians (CHEST) at 2595 Patriot Boulevard, Glenview, IL 60026; Phone: Phone: 224-521-9800; Fax: 224-521-9801; Web site: www.chestnet.org External Web Site Policy.

NQMC Disclaimer

The National Quality Measures Clearinghouse™ (NQMC) does not develop, produce, approve, or endorse the measures represented on this site.

All measures summarized by NQMC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public and private organizations, other government agencies, health care organizations or plans, individuals, and similar entities.

Measures represented on the NQMC Web site are submitted by measure developers, and are screened solely to determine that they meet the NQMC Inclusion Criteria.

NQMC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or its reliability and/or validity of the quality measures and related materials represented on this site. Moreover, the views and opinions of developers or authors of measures represented on this site do not necessarily state or reflect those of NQMC, AHRQ, or its contractor, ECRI Institute, and inclusion or hosting of measures in NQMC may not be used for advertising or commercial endorsement purposes.

Readers with questions regarding measure content are directed to contact the measure developer.

About NQMC Measure Summaries

NQMC provides structured summaries containing information about measures and their development.

Measure Summary FAQs


Measure Summaries

New This Week

View more and sign up for our Newsletter

Get Adobe Reader